Extended indication

Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged

Therapeutic value

No estimate possible yet

Registration phase

Registration application pending

Product

Active substance

Exenatide

Domain

Metabolism and Endocrinology

Reason of inclusion

Indication extension

Main indication

Diabetes

Extended indication

Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged 10 years and above

Proprietary name

Bydureon

Manufacturer

AstraZeneca

Route of administration

Subcutaneous

Therapeutical formulation

Injection

Budgetting framework

Extramural (GVS)

Registration

Registration route

Decentralised

ATMP

No

Submission date

August 2021

Expected Registration

June 2022

Orphan drug

No

Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.